Abstract 592P
Background
Debate surrounds the surgical management of Goblet cell adenocarcinoma (GCA). However, right hemicolectomy (RHC) remains the standard surgical choice for GCA.
Methods
1154 and 867 patients with GCA were extracted from U.S. Surveillance, Epidemiology, and End Results (SEER) and National Cancer Registration and Analysis Service (NCRAS) databases respectively after excluding patients with missing data. Two clusters for each cohort were created using an unsupervised machine learning K-means model (cluster 0, cluster 1). Clustering was evaluated using silhouette (S), Davies Boulden (DB) and Caliniski Harabasz (CH) scores. Clusters were visualised using principal component analysis (PCA) and T-distributed stochastic neighbour embedding (T-SNE). SHapley Additive exPlanations (SHAP) identified clinical features that were the most useful in clustering. Kaplan Meier (KM) statistics and graphs were generated. Decision trees were developed to cluster individual patients in each of the two clusters.
Results
PCA and T-SNE visualisations showed distinct clusters with some overlap in both cohorts. SHAP revealed tumour size and stage as important variables for clustering in SEER, while age and stage were key variables in NCRAS. Clusters description and survival are shown in the table. The two clusters were statistically different in survival based on Cox regression, Log-rank test and KM statistics in both cohorts. Appendectomy and RHC showed similar survival rates across both cohorts and within each cluster of both cohorts. Table: 592P
Characteristics of clusters and 5-year survival rates
Characteristic | Clustrer 0Favourable survival | Cluster 1Unfavourable survival |
Median age, years (SEER) | 58 | 59 |
Male sex, % (SEER) | 48 | 54 |
Localised stage, % (SEER) | 64 | 33 |
Distant stage, % (SEER) | 3 | 19 |
Tumour size, median mm (SEER) | 14 | 50 |
5-year survival, % (95% CI) (SEER) | 85(82-88) | 72(59-72) |
Median age, years (NCRAS) | 48 | 68 |
Male sex, % (NCRAS) | 56 | 43 |
Localised stage, % (NCRAS) | 90 | 81 |
Distant stage, % (NCRAS) | 4 | 9 |
5-year survival, % (95% CI) (NCRAS) | 87(83-91) | 61(57-66) |
Conclusions
After categorising cases into two clusters using unsupervised machine learning, RHC and appendectomy demonstrated comparable survival rates among patients with GCA. Machine learning could facilitate clinicians in exploring the impact of various treatment approaches on survival outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hampshire Hospitals NHS Foundation Trust.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
597P - Hyperthermic intraperitoneal chemotherapy for the management of gastrointestinal cancers: An analysis of the immediate postoperative period
Presenter: Filipa Simões
Session: Poster session 16
598TiP - PRODIGE 86 (FFCD 2103 - GONO) – FOLFIRINOX SBA: Phase II randomized trial to evaluate mFOLFIRINOX and mFOLFOX in the treatment of locally advanced or metastatic small bowel adenocarcinoma
Presenter: Thomas Aparicio
Session: Poster session 16
599TiP - PRABITAS study: A pragmatic, randomized, phase III trial of biweekly vs. conventional use of trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer
Presenter: Tomoki Sakakida
Session: Poster session 16
600TiP - A randomized blinded phase II study of ompenaclid (RGX-202-01) vs placebo in combination with FOLFIRI plus bevacizumab (BEV) in patients (pts) with previously treated RAS mutated (RASmt) advanced/metastatic colorectal cancer (mCRC)
Presenter: Maria Elena Elez Fernandez
Session: Poster session 16
601TiP - A multicenter randomized clinical trial evaluating the negative hyperselection of patients with RAS/BRAF wild-type metastatic colorectal cancer who are eligible for anti-EGFR therapy
Presenter: Ilya Pokataev
Session: Poster session 16
602TiP - Radical concurrent chemoradiotherapy with DDP/5-FU and PD-1 antibody for non-metastatic rectal squamous cell carcinoma: A multicenter, prospective, single-arm, phase II study
Presenter: Jun Huang
Session: Poster session 16
454P - Tetrahydrocannabinol (THC) / cannabidiol (CBD) oral solution in combination with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed glioblastoma: Phase Ib GEINO-1601 trial
Presenter: Juan Manuel Sepúlveda
Session: Poster session 16
455P - Phase II trial of hippocampus-avoidance whole-brain radiation therapy with simultaneous integrated boost for multiple brain metastases in non-small cell lung cancer
Presenter: Yatian Liu
Session: Poster session 16
456P - Real-world data of IDH mutant gliomas in Spain, a RETSINE: GEINO study
Presenter: Manuel Alejandro Mazariegos-Rubi
Session: Poster session 16
457P - Progression-free survival 2 (PFS2) as a surrogate for overall survival in a multicentric real-world data cohort of glioblastoma (GBM)
Presenter: Jesus Yaringaño Cerna
Session: Poster session 16